Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Phase 2 Merus founded in 2003 trades at US$58

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 24, 2024 12:35pm

102 Views

Post# 36056114

RE:RE:Phase 2 Merus founded in 2003 trades at US$58

For Merus a confirmed 50% ORR in petosemtamab’s Keytruda combo trial met analysts’ base case expectations, but this was always going to be about the one additional unconfirmed response in the 10 patients evaluated, which would have taken the ORR to 60%., according to one biotech analyst.Truist Securities analysts wrote: “Given how early it is at the data cutoff we think it is likely that this patient will be confirmed with subsequent follow-up."

Currently Mesus is trading at US$59.93 per share +15.86% on limited evaluable patient data.

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for Oct. 7, 2024